Het prostaatcentrum van het OLV Ziekenhuis neemt actief deel aan klinische studies voor nieuwe medicatie. Deze studies bieden patiënten soms de kans om in een vroeg stadium nieuwe medicatie toegediend te krijgen.

Hier vindt u een overzicht van de studies over prostaatkanker waaraan het OLV Ziekenhuis de jongste tien jaar deelnam.

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy; Protocol 56021927PCR3003; Phase 3 (April 2016 – open for inclusion)
A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer. NCT02236637 (June 2013 – open for inclusion)
Stereotactic Body Radiation Therapy for cT1c – cT3a Prostate Cancer With a Low Risk of Nodal Metastases (≤ 20%, Roach Index): a Novalis Circle Phase II Prospective Randomized Trial. NCT01764646 (Sept 2012 – open for inclusion)
A Prospective Randomised Phase III Study of Androgen Deprivation Therapy With or Without Local Radiotherapy With or Without Abiraterone Acetate and Prednisone in Patient With Metastatic Hormone-naïve Prostate Cancer. NCT01957436 (Oct 2013 – open for inclusion)
Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer. NCT02440802 (April 2013 – open for inclusion)
Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy. NCT01867710 (Juli 2013 – April 2015)
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100. NCT01605227 (Juni 2012 – Sept 2014)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy. NCT00638690 (Mei 2008 – August 2010)
Randomized phase II trial of Docetaxel (Taxotere) and Oblimersen vs Taxotere alone in patients with HRPC EORTC-30021-GUCG. NCT00085228 (April 2004 – Jan 2006)
Phase IV, Non-interventional, Prospective, Open Label, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients. NCT01793077 (Dec 2011 – Dec 2013)
The INPACT Study (Improving With Nadroparin the Prognosis in Advanced Cancer Treatment). A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate. NCT00312013 (Mei 2006 – Juli 2009)
Phase III study comparing early versus delayed orchidectomy, or early versus delayed treatment with a depot LHRH analogue (Buserelin) respectively, in patients with asymptomatic non metastatic prostate cancer       T0-4 N0-2 M0 EORTC-30891-GUCG NCT01819285 (1990-2004)